Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care.
Oncotarget
Kong, Say Li SL; Liu, Xingliang X; Suhaimi, Nur-Afidah Mohamed NM; Koh, Kenneth Jia Hao KJH; Hu, Min M; Lee, Daniel Yoke San DYS; Cima, Igor I; Phyo, Wai Min WM; Lee, Esther Xing Wei EXW; Tai, Joyce A JA; Foong, Yu Miin YM; Vo, Jess Honganh JH; Koh, Poh Koon PK; Zhang, Tong T; Ying, Jackie Y JY; Lim, Bing B; Tan, Min-Han MH; Hillmer, Axel M AM
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Oncotarget
Geißler, Anna-Lena AL; Geißler, Miriam M; Kottmann, Daniel D; Lutz, Lisa L; Fichter, Christiane D CD; Fritsch, Ralph R; Weddeling, Britta B; Makowiec, Frank F; Werner, Martin M; Lassmann, Silke S
Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples.
Plos One
Betge, Johannes J; Kerr, Grainne G; Miersch, Thilo T; Leible, Svenja S; Erdmann, Gerrit G; Galata, Christian L CL; Zhan, Tianzuo T; Gaiser, Timo T; Post, Stefan S; Ebert, Matthias P MP; Horisberger, Karoline K; Boutros, Michael M
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Bmc Cancer
Pignochino, Ymera Y; Sarotto, Ivana I; Peraldo-Neia, Caterina C; Penachioni, Junia Y JY; Cavalloni, Giuliana G; Migliardi, Giorgia G; Casorzo, Laura L; Chiorino, Giovanna G; Risio, Mauro M; Bardelli, Alberto A; Aglietta, Massimo M; Leone, Francesco F